{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-108821","form_type":"8-K","ticker":"OGN","cik":"0001821825","company_name":"Organon & Co.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.619498+00:00","generated_at":"2026-05-16T22:33:53.397075+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Organon Q3 revenue $1.6B, adj. EPS $1.01; FY2025 guidance lowered","bullets":["Q3 revenue $1.602B (+1% as-reported, -1% ex-FX); net income $160M vs $359M YoY (-55%).","GAAP diluted EPS $0.61; non-GAAP adjusted diluted EPS $1.01 (up 16% YoY).","Adjusted EBITDA $518M (32.3% margin), up from $459M (29.0%) YoY.","FY2025 revenue guidance cut to $6.200-6.250B; Adj EBITDA margin guidance ~31.0% (lowered).","Nexplanon sales down 9% ex-FX due to lower U.S. government funding; Biosimilars up 19% on Hadlima."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-108821","json":"https://secwatch.observer/filing/0001104659-25-108821.json","markdown":"https://secwatch.observer/filing/0001104659-25-108821.md","text":"https://secwatch.observer/filing/0001104659-25-108821.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821825/000110465925108821/0001104659-25-108821-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821825/000110465925108821/tm2530711d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:33:53.397075+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}